Silas Inman

The FDA has approved guselkumab for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Revefenacin improved trough FEV1 versus placebo in two phase 3 trials for COPD.

Benralizumab led to a 75% reduction in the use of oral corticosteroids for severe asthma.

PBI-4050 slowed or stopped declines in lung function in patients with IPF.

MK-7264 reduced cough frequency by 37% for patients with chronic cough.

ICOS and CD28 expression levels on CD4 T cells effectively predicted survival for patients with idiopathic pulmonary fibrosis.

Acute exacerbations of COPD dramatically increased the risk of CVD events.

The Synthroid brand of levothyroxine improved thyroid-stimulating hormone (TSH) levels by a significantly greater margin compared with generic versions of the synthetic T4 (LT4) hormones for patients with hypothyroidism.

A supplemental new drug application has been submitted to the US Food and Drug Administration (FDA) for 10-mg rivaroxaban as a treatment to reduce the risk of recurrent venous thromboembolism (VTE) after at least six months of standard anticoagulation therapy.

Republicans in the House of Representatives have proposed a replacement bill for the Affordable Care Act, which it hopes will pass Congress within the next 30 days.

The expanded indication was granted under the FDA's priority review program.

The FDA has approved brodalumab for moderate-to-severe plaque psoriasis in patients who are eligible for systemic therapy or phototherapy and who have failed to respond or stopped responding to other systemic therapies.

Just hours after taking the oath of office, President Donald J. Trump has already signed an executive order calling for the prompt repeal of the Affordable Care Act (ACA).

The FDA has issued a complete response letter for the oral and intravenous antibiotic solithromycin as a treatment for patients with community-acquired bacterial pneumonia, due to concerns over hepatotoxicity and manufacturing issues.

The FDA has approved Adynovate (PEGylated antihemophilic factor [recombinant]) as a treatment for hemophilia A in pediatric patients under 12 years of age and for both adults and pediatric patients in the surgical setting, based on findings from a phase 3 trial.

The FDA has approved nusinersen as a treatment for children and adults with spinal muscular atrophy (SMA), an often fatal genetic disease affecting muscle strength and movement.